Teva to Initiate Third Phase III Trial of Oral Laquinimod for the Treatment of Relapsing Remitting Multiple Sclerosis
08:00 EDT 8 Aug 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Active Biotech
(NASDAQ OMX NORDIC: ACTI) provided today an update on the clinical
development program of once-daily oral laquinimod for the treatment of
relapsing-remitting mu...
Other Sources for this Article
Teva Pharmaceutical Industries Ltd.
IR:
Kevin C. Mannix
United
States
215-591-8912
or
Joseph Marczely
United States
267-468-4281
or
Tomer
Amitai
Israel
972 (3) 926-7656
or
PR:
Hadar
Vismunski-Weinberg
Israel
972 (3) 926-7687
or
Denise
Bradley
United States
215-591-8974
or
Active
Biotech
Tomas Leanderson
Active Biotech AB
+46-46-19-20-95
or
Hans
Kolam
Active Biotech AB
+46-46-19-20-44
More From BioPortfolio on "Teva to Initiate Third Phase III Trial of Oral Laquinimod for the Treatment of Relapsing Remitting Multiple Sclerosis"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
